-
Sex Differences in Angiotensin II-Induced Hypertension in Mi
2026-06-25
This study provides the first direct evidence that male and female mice develop angiotensin II-induced hypertension with markedly different severity, highlighting a critical role for sex hormones and autonomic regulation in blood pressure control. These findings refine our understanding of cardiovascular disease mechanisms and offer a rigorous model for dissecting sex-specific hypertension pathways.
-
Intracellular Aminopeptidase Inhibition in Myeloma Cell Prol
2026-06-25
Grujić and Renko's study establishes that bestatin and actinonin suppress myeloma cell proliferation mainly through intracellular, not cell-surface, mechanisms. By leveraging drug efflux modulators including verapamil, the research clarifies how aminopeptidase inhibitor activity and cellular transport intersect, offering new directions for targeting drug resistance in cancer models.
-
Optimizing RAS Assays: Angiotensin 1/2 (5-7) (SKU A1049) in
2026-06-24
This article addresses critical workflow challenges in renin-angiotensin system (RAS) and cell viability assays, demonstrating how Angiotensin 1/2 (5-7) (SKU A1049) delivers superior reproducibility and protocol compatibility. Drawing on recent peer-reviewed data and laboratory best practices, it guides researchers in selecting and deploying this high-purity H2N-Ile-His-Pro-OH peptide for cardiovascular and infectious disease models.
-
BCECF: Advanced Strategies for Extracellular pH Sensing in D
2026-06-23
Explore the pivotal role of BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein) as a fluorescent pH probe for ion transport and microenvironmental pH regulation. This article delivers unique, practical insights for leveraging BCECF in complex disease models, drawing on new evidence and expert protocol guidance.
-
CPI-613: Advancing Tumor Metabolism and Immune Modulation Re
2026-06-23
This article explores the mechanistic rationale and translational strategies for leveraging CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) in tumor cell metabolism studies, with a focus on cholangiocarcinoma, immune evasion, and chemotherapy resistance. By integrating recent findings on PDHA1 succinylation and alpha-ketoglutaric acid accumulation, it provides actionable guidance for researchers aiming to design robust apoptosis assays and therapeutic synergy protocols. The discussion uniquely bridges metabolic enzyme inhibition with tumor immunology, highlighting APExBIO's CPI-613 as a catalyst for next-generation cancer research.
-
Optimizing Apoptosis Assays Using CA-074 Me (Cathepsin B inh
2026-06-22
This evidence-based guide explores how CA-074 Me (Cathepsin B inhibitor, SKU A8239) enables reproducible, sensitive, and mechanistically insightful research in cell death and lysosomal pathway studies. Drawing on peer-reviewed findings and real-world lab scenarios, it highlights experimental design, protocol optimization, and vendor selection best practices.
-
28S rRNA Expansion Segments Drive Nucleolar Layer Complexity
2026-06-22
Wei et al. elucidate how multivalent expansion segments (ESs) in 28S rRNA enable the assembly of multilayered nucleolar architecture through RNA-RNA interactions. Their findings reveal the modular and transferable nature of these ESs, with implications for reconstituting nucleolar compartments and advancing RNA labeling strategies in molecular biology.
-
Distinct Roles of GluN2A/B in Orofacial Allodynia via Connex
2026-06-21
This study uncovers how the GluN2A and GluN2B subunits of the NMDA receptor distinctly mediate the expression of connexin and pannexin channels in trigeminal ganglion cells during temporomandibular joint (TMJ) inflammation. These findings clarify peripheral sensitization mechanisms in orofacial inflammatory allodynia and suggest new molecular targets for pain management.
-
Nanoparticle-Mediated mRNA Delivery Reverses Trastuzumab Res
2026-06-20
The referenced study introduces a tumor microenvironment (TME)-responsive nanoparticle system for systemic delivery of PTEN mRNA, aimed at overcoming trastuzumab resistance in HER2-positive breast cancer. This approach demonstrates the therapeutic relevance of restoring PTEN expression to inhibit PI3K/Akt signaling, offering an innovative strategy to address a critical challenge in antibody-based cancer therapy.
-
Ketone Body-Mediated Ferroptosis Inhibition in Stroke Neurop
2026-06-19
This study demonstrates that remote ischemic postconditioning (RIPostC) confers neuroprotection in experimental stroke by promoting ketone body-driven inhibition of ferroptosis. The findings reveal a mechanistic link between metabolic adaptation and suppression of iron-dependent lipid peroxidation, with implications for designing new interventions targeting energy metabolism and cell death in neurological injury.
-
Standardized Whole-Blood Stimulation Unveils Immunometabolic
2026-06-19
This protocol study introduces a rigorous framework for analyzing human immune responses via standardized whole-blood stimulation combined with metabolic modulation. By enabling reproducible assessment of how metabolic pathways regulate cytokine production, the research advances immunometabolism studies and supports translational immune intervention strategies.
-
BR101801–Venetoclax Synergy in DLBCL via Triple Targeting Pa
2026-06-18
This study demonstrates that combining BR101801, a PI3K/DNA-PK inhibitor, with Venetoclax (ABT-199) yields potent synergistic antitumor effects in double-hit diffuse large B-cell lymphoma (DLBCL) by simultaneously targeting c-Myc, Bcl-2, and Mcl-1 pathways. The findings suggest a promising combinatorial approach to overcome resistance in aggressive DLBCL subtypes and inform future therapeutic strategies.
-
Pharmacokinetics and PK/PD Rationale for Cefazedone in CAP T
2026-06-18
This article examines a clinical pharmacokinetic and pharmacodynamic study evaluating intravenous Cefazedone for mild to moderate community-acquired pneumonia. The research demonstrates that a 2 g every 12 hours regimen achieves optimal fT>MIC and clinical cure rates, supporting its rational use for infections caused by susceptible bacteria.
-
SARS-CoV-2 Nucleocapsid Suppresses GADD34-Mediated Immunity
2026-06-17
This study elucidates how the SARS-CoV-2 nucleocapsid protein subverts host innate immunity by sequestering GADD34 mRNA in atypical foci, disrupting the IRF3-mediated antiviral response. The findings highlight a novel viral strategy with implications for antiviral research and potential therapeutic development.
-
Optimizing Excitotoxicity Assays with NMDA (N-Methyl-D-aspar
2026-06-17
This article provides a scenario-driven, evidence-based guide to maximizing the reliability and reproducibility of excitotoxicity and oxidative stress assays using NMDA (N-Methyl-D-aspartic acid), SKU B1624. Drawing from recent literature and practical laboratory challenges, we demonstrate how APExBIO’s high-purity NMDA supports robust modeling in neurodegenerative disease research and cell viability workflows.